Phaseline

Companies › Adrenas Therapeutics

Adrenas Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AAV BBP-631
AAV5-mediated gene therapy delivering CYP21A2
CYP21A2Phase 1Congenital Adrenal HyperplasiaFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04783181AAV BBP-631Phase 1Congenital Adrenal HyperplasiaGenitourinaryFeb 2029

Targets

CYP21A2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.